CN103966350A - CST1mRNA和CST4mRNA或其编码的蛋白质在制备尿道癌标志物中的应用及其试剂盒 - Google Patents
CST1mRNA和CST4mRNA或其编码的蛋白质在制备尿道癌标志物中的应用及其试剂盒 Download PDFInfo
- Publication number
- CN103966350A CN103966350A CN201410235169.5A CN201410235169A CN103966350A CN 103966350 A CN103966350 A CN 103966350A CN 201410235169 A CN201410235169 A CN 201410235169A CN 103966350 A CN103966350 A CN 103966350A
- Authority
- CN
- China
- Prior art keywords
- cystatin
- seq
- cst4mrna
- cst1mrna
- urethral carcinoma
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/81—Protease inhibitors
- G01N2333/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
- G01N2333/8139—Cysteine protease (E.C. 3.4.22) inhibitors, e.g. cystatin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Pathology (AREA)
- Biomedical Technology (AREA)
- Analytical Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Oncology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Cell Biology (AREA)
- Hospice & Palliative Care (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Description
标准品编号 | 浓度(copy/μL) |
STD1 | 100000 |
STD2 | 10000 |
STD3 | 1000 |
STD4 | 100 |
标准品编号 | 浓度(copy/μL) |
STD1 | 100000 |
STD2 | 10000 |
STD3 | 1000 |
STD4 | 100 |
患者编号 | 治疗前后浓度变化百分比 | 临床评价 |
1 | 升高15% | 无效 |
2 | 下降37% | 改善 |
3 | 降低88% | 疗效显著 |
4 | 降低49% | 改善 |
5 | 升高1% | 无效 |
6 | 降低36% | 改善 |
7 | 降低79% | 疗效显著 |
8 | 降低36% | 无效 |
9 | 降低8% | 无效 |
10 | 降低38% | 改善 |
患者编号 | 6周 | 3个月 | 6个月 | 9个月 | 临床评价 |
1 | 0.18 | 0.16 | 0.19 | 0.20 | 无进展生存 |
2 | 0.46 | 0.59 | 0.64 | 0.75 | 转移复发 |
3 | 0.38 | 0.41 | 0.55 | 0.60 | 无进展生存 |
4 | 0.29 | 0.40 | 0.36 | 0.45 | 无进展生存 |
5 | 0.48 | 0.50 | 0.65 | 0.74 | 转移复发 |
6 | 0.24 | 0.26 | 0.31 | 0.29 | 无进展生存 |
患者编号 | 治疗前后浓度变化百分比 | 临床评价 |
1 | 升高2% | 无效 |
2 | 下降39% | 改善 |
3 | 下降85% | 疗效显著 |
4 | 下降50% | 改善 |
5 | 升高13% | 无效 |
6 | 下降39% | 改善 |
7 | 下降90% | 疗效显著 |
8 | 下降43% | 无效 |
9 | 下降9% | 无效 |
10 | 下降44% | 改善 |
患者编号 | 6周 | 3个月 | 6个月 | 9个月 | 临床评价 |
1 | 0.38 | 0.46 | 0.39 | 0.32 | 无进展生存 |
2 | 0.36 | 0.49 | 0.59 | 0.71 | 转移复发 |
3 | 0.28 | 0.21 | 0.25 | 0.26 | 无进展生存 |
4 | 0.49 | 0.58 | 0.46 | 0.45 | 无进展生存 |
5 | 0.56 | 0.58 | 0.65 | 0.79 | 转移复发 |
6 | 0.37 | 0.37 | 0.39 | 0.41 | 无进展生存 |
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410235169.5A CN103966350B (zh) | 2014-05-29 | 2014-05-29 | CST1 mRNA和CST4 mRNA或其编码的蛋白质在制备尿道癌标志物中的应用及其试剂盒 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410235169.5A CN103966350B (zh) | 2014-05-29 | 2014-05-29 | CST1 mRNA和CST4 mRNA或其编码的蛋白质在制备尿道癌标志物中的应用及其试剂盒 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103966350A true CN103966350A (zh) | 2014-08-06 |
CN103966350B CN103966350B (zh) | 2015-06-10 |
Family
ID=51236351
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201410235169.5A Active CN103966350B (zh) | 2014-05-29 | 2014-05-29 | CST1 mRNA和CST4 mRNA或其编码的蛋白质在制备尿道癌标志物中的应用及其试剂盒 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN103966350B (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2021097358A1 (en) * | 2019-11-14 | 2021-05-20 | Gen-Probe Incorporated | Compositions and methods for capturing target nucleic acids |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101985651A (zh) * | 2010-04-30 | 2011-03-16 | 苏州工业园区为真生物医药科技有限公司 | 胃肠肿瘤诊断和预示的新分子标记 |
WO2013104102A1 (zh) * | 2012-01-09 | 2013-07-18 | 苏州工业园区为真生物医药科技有限公司 | 乳腺癌诊断和预示的标志物 |
CN103667444A (zh) * | 2013-09-29 | 2014-03-26 | 中山大学附属第三医院 | 一种与胰腺癌相关的肿瘤标记物及其应用 |
CN103740854A (zh) * | 2014-01-29 | 2014-04-23 | 中山大学附属第三医院 | 一种肿瘤标记物及其在制备结直肠癌诊断试剂中的应用 |
-
2014
- 2014-05-29 CN CN201410235169.5A patent/CN103966350B/zh active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101985651A (zh) * | 2010-04-30 | 2011-03-16 | 苏州工业园区为真生物医药科技有限公司 | 胃肠肿瘤诊断和预示的新分子标记 |
WO2013104102A1 (zh) * | 2012-01-09 | 2013-07-18 | 苏州工业园区为真生物医药科技有限公司 | 乳腺癌诊断和预示的标志物 |
CN103667444A (zh) * | 2013-09-29 | 2014-03-26 | 中山大学附属第三医院 | 一种与胰腺癌相关的肿瘤标记物及其应用 |
CN103740854A (zh) * | 2014-01-29 | 2014-04-23 | 中山大学附属第三医院 | 一种肿瘤标记物及其在制备结直肠癌诊断试剂中的应用 |
Non-Patent Citations (2)
Title |
---|
TURK V ET AL.: "Cystatins:biochemical and structural properties,and medical relevance", 《FRONT BIOSCI》, vol. 13, 1 May 2008 (2008-05-01), pages 5406 - 5420 * |
YONEDA K ET AL.: "Identification of cystatin SN as a novel tumor marker for colorectal cancer", 《INT J ONCOL》, vol. 35, no. 1, 31 July 2009 (2009-07-31), pages 33 - 40, XP002547543, DOI: 10.3892/ijo_00000310 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2021097358A1 (en) * | 2019-11-14 | 2021-05-20 | Gen-Probe Incorporated | Compositions and methods for capturing target nucleic acids |
Also Published As
Publication number | Publication date |
---|---|
CN103966350B (zh) | 2015-06-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103898205B (zh) | 半胱氨酸蛋白酶抑制剂sn的应用 | |
CN103966351B (zh) | CST1mRNA和CST4mRNA或其编码的蛋白质在制备肾癌标志物中的应用及其试剂盒 | |
CN105671181A (zh) | 用于检测肺癌的基因标志物、引物、探针及试剂盒 | |
Li et al. | miR-26a-5p inhibit gastric cancer cell proliferation and invasion through mediated Wnt5a | |
CN104004840A (zh) | 用于早期筛查与诊断前列腺癌的试剂盒 | |
CN109576370A (zh) | 用于膀胱癌诊断和复发监控的生物标志物及检测试剂盒 | |
Wang et al. | Plasma expression of miRNA-21,− 214,− 34a, and-200a in patients with persistent HPV infection and cervical lesions | |
Wang et al. | miR-145-5p inhibits psoriasis progression by regulating the Wnt/β-catenin pathway | |
CN103940996B (zh) | Cystatin SN和AFP在制备诊断和预示肝癌标志物中的应用 | |
Gong et al. | High expression of C10orf91 and LINC01224 in hepatocellular carcinoma and poor prognosis | |
Ling et al. | MMP-2 and MMP-9 gene polymorphisms act as biological indicators for ulinastatin efficacy in patients with severe acute pancreatitis | |
CN103966350B (zh) | CST1 mRNA和CST4 mRNA或其编码的蛋白质在制备尿道癌标志物中的应用及其试剂盒 | |
Sun et al. | Detection of type IV collagenase activity in malignant ascites | |
CN104046685A (zh) | 用于胃癌的诊断和预后的表观遗传生物标志物adamts9 | |
CN103966348B (zh) | CST1mRNA和CST4mRNA或其编码的蛋白质在制备膀胱癌标志物中的应用及其试剂盒 | |
CN105063191A (zh) | 一组用于口腔中幽门螺杆菌的实时荧光定量pcr检测的特异性引物和探针 | |
CN103966352B (zh) | Pca3、cst1和cst4在制备前列腺癌标志物中的应用及其试剂盒 | |
CN105154581A (zh) | 一种非小细胞肺癌的诊断和预示方法和生物检测试剂盒 | |
Ma et al. | Liver-specific LINC01146, a promising prognostic indicator, inhibits the malignant phenotype of hepatocellular carcinoma cells both in vitro and in vivo | |
Chiu et al. | Overexpression of matrix metalloproteinase-9 in adolescents with primary spontaneous pneumothorax for surgical intervention | |
CN103849683B (zh) | 前列腺癌尿液检测试剂盒及其应用 | |
Abou-Zeid et al. | HOXA9 gene promotor methylation and copy number variation of SOX2 and HV2 genes in cell free DNA: A potential diagnostic panel for non-small cell lung cancer | |
Komatsuda et al. | Serum procalcitonin levels in patients with myeloperoxidase-antineutrophil cytoplasmic antibodies-associated glomerulonephritis | |
JPWO2019117269A1 (ja) | 膵がんの検出を補助する方法 | |
CN105349640A (zh) | 一种用于诊断和预示乳腺癌的生物标志物和检测试剂盒 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
ASS | Succession or assignment of patent right |
Owner name: SUZHOU MICRO DIAG BIOMEDICINE CO., LTD. Free format text: FORMER OWNER: SHANGHAI DUWEI MEDICAL TECHNOLOGY CO., LTD. Effective date: 20141103 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 201507 JINSHAN, SHANGHAI TO: 215123 SUZHOU, JIANGSU PROVINCE |
|
TA01 | Transfer of patent application right |
Effective date of registration: 20141103 Address after: Suzhou City, Jiangsu Province, Suzhou Industrial Park, 215123 Street No. 218 Nano Technology Park building C4 Room 301 Applicant after: Suzhou Micro Diag Biomedicine Co., Ltd. Address before: 201507 Shanghai city Jinshan District Caojing town industry Road No. 80 Applicant before: SHANGHAI DUWEI MEDICAL TECHNOLOGY CO., LTD. |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20151124 Address after: Suzhou City, Jiangsu province 215000 Jinji Lake Avenue, Suzhou Industrial Park, No. 99 Suzhou West North Building 16 nm Patentee after: PUSHI HUAKANG JIANGSU MEDICAL TECHNOLOGY CO., LTD. Address before: Suzhou City, Jiangsu Province, Suzhou Industrial Park, 215123 Street No. 218 Nano Technology Park building C4 Room 301 Patentee before: Suzhou Micro Diag Biomedicine Co., Ltd. |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20211203 Address after: 200120 all parts of floor 4, building 1, No. 271, Hong Kong Macao Road, pilot Free Trade Zone, Pudong New Area, Shanghai Patentee after: SHANGHAI LIANGRUN BIOMEDICAL TECHNOLOGY CO.,LTD. Address before: 215000 building 16, Northwest District, Suzhou nano City, 99 Jinjihu Avenue, Suzhou Industrial Park, Suzhou City, Jiangsu Province Patentee before: PUSHI HUAKANG JIANGSU MEDICAL TECHNOLOGY Co.,Ltd. |